AR088267A1 - Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos - Google Patents
Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usosInfo
- Publication number
- AR088267A1 AR088267A1 ARP120103742A ARP120103742A AR088267A1 AR 088267 A1 AR088267 A1 AR 088267A1 AR P120103742 A ARP120103742 A AR P120103742A AR P120103742 A ARP120103742 A AR P120103742A AR 088267 A1 AR088267 A1 AR 088267A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivative
- blood coagulation
- facvii
- conjugate
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un derivado del factor de coagulación sanguínea VII, un derivado del factor de coagulación sanguínea VIIa; cada uno de los conjugados FacVII y FacVlIa se prepara por unión a un polímero que puede prolongar la vida media en sangre del derivado; cada uno de los complejos Fac VII y VIIa se prepara por unión de un vehículo al conjugado; genes que codifican los derivados FacVII y Fac Vila; vectores de expresión que comprenden los genes; transformantes introducidos con los vectores de expresión; un método para preparar los derivados FacVII y FacVlIa usando los transformantes: un método para preparar el conjugado y el complejo FacVIIa; un complejo FacVIIa preparado con el método; una composición farmacéutica para la prevención o el tratamiento de hemofilia que comprende al derivado, conjugado o complejo como ingrediente activo; y una composición farmacéutica para la coagulación sanguínea que comprende al derivado, conjugado o complejo como ingrediente activo. Además, se relaciona con un método para prevenir o tratar hemofilia o para promover la coagulación sanguínea, que comprende administrar a un sujeto una cantidad terapéuticamente eficaz de la composición. El derivado FacVII o FacVIIa se puede conjugar a un vehículo que puede mejorar la vida media en sangre manteniendo al mismo tiempo la actividad de FacVIe o FacVlIa, y se pueden utilizar ampliamente en el desarrollo de agentes profilácticos o terapéuticos eficaces para la hemofilia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110102099 | 2011-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088267A1 true AR088267A1 (es) | 2014-05-21 |
Family
ID=48044320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103742A AR088267A1 (es) | 2011-10-06 | 2012-10-05 | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9597378B2 (es) |
| EP (2) | EP2763693A4 (es) |
| JP (1) | JP6108630B2 (es) |
| KR (1) | KR20130037659A (es) |
| CN (1) | CN103974716B (es) |
| AR (1) | AR088267A1 (es) |
| AU (1) | AU2012319308B2 (es) |
| BR (1) | BR112014008224A2 (es) |
| CA (1) | CA2851223A1 (es) |
| IL (1) | IL231930A0 (es) |
| MX (1) | MX354493B (es) |
| MY (1) | MY168754A (es) |
| RU (1) | RU2620072C2 (es) |
| SG (1) | SG11201401205UA (es) |
| TW (1) | TWI565715B (es) |
| WO (1) | WO2013051900A2 (es) |
| ZA (1) | ZA201402745B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| TWI641382B (zh) * | 2013-01-31 | 2018-11-21 | 韓美藥品股份有限公司 | 於包含因子ｖｉｉ之組成物中使病毒失活之方法 |
| CN103397009B (zh) * | 2013-08-16 | 2015-06-03 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
| CN103599527A (zh) * | 2013-08-16 | 2014-02-26 | 安源生物科技(上海)有限公司 | 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物 |
| KR20150026024A (ko) * | 2013-08-30 | 2015-03-11 | 한미약품 주식회사 | 인간 혈액응고 7인자 유도체의 대량 생산 방법 |
| CN117065044A (zh) * | 2014-03-31 | 2023-11-17 | 韩美药品株式会社 | 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法 |
| WO2017083321A1 (en) * | 2015-11-10 | 2017-05-18 | Sun Chemical Corporation | Alkoxylated dispersing agents |
| KR102041671B1 (ko) * | 2017-05-08 | 2019-11-28 | 가톨릭대학교 산학협력단 | β-아밀로이드 단백질의 응집을 억제하는 생체친화적 펩타이드 |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
| US11786580B2 (en) | 2018-04-23 | 2023-10-17 | Emory University | VIP and VIP agonists, nanoparticles, and uses in inflammatory T-cell mediated disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2278123C2 (ru) * | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
| CA2441580A1 (en) * | 2001-03-22 | 2002-10-03 | Novo Nordisk Health Care Ag | Coagulation factor vii derivatives |
| US7235638B2 (en) * | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
| AU2003242507A1 (en) | 2002-07-12 | 2004-02-02 | Novo Nordisk A/S | A tissue factor binding immunoconjugate comprising factor viia |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2005032581A2 (en) * | 2003-10-07 | 2005-04-14 | Novo Nordisk Health Care Ag | Hybrid molecules having factor vii/viia activity |
| AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
| US20090041744A1 (en) * | 2005-06-17 | 2009-02-12 | Novo Nordisk Healthcare A/G | Dimeric and Multimeric FVIIa Compounds |
| US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| KR100880509B1 (ko) | 2006-10-16 | 2009-01-28 | 한미약품 주식회사 | 재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법 |
| KR101104684B1 (ko) | 2008-12-02 | 2012-01-16 | 이화여자대학교 산학협력단 | 관찰 방향 및 조명을 고려한 피부 질감 렌더링 방법 및 그 장치 |
| US20120121613A1 (en) * | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
-
2012
- 2012-10-05 RU RU2014115291A patent/RU2620072C2/ru not_active IP Right Cessation
- 2012-10-05 AR ARP120103742A patent/AR088267A1/es unknown
- 2012-10-05 US US14/349,925 patent/US9597378B2/en not_active Expired - Fee Related
- 2012-10-05 SG SG11201401205UA patent/SG11201401205UA/en unknown
- 2012-10-05 MX MX2014004099A patent/MX354493B/es active IP Right Grant
- 2012-10-05 JP JP2014534483A patent/JP6108630B2/ja not_active Expired - Fee Related
- 2012-10-05 CN CN201280060378.XA patent/CN103974716B/zh not_active Expired - Fee Related
- 2012-10-05 AU AU2012319308A patent/AU2012319308B2/en not_active Ceased
- 2012-10-05 BR BR112014008224A patent/BR112014008224A2/pt not_active Application Discontinuation
- 2012-10-05 MY MYPI2014000988A patent/MY168754A/en unknown
- 2012-10-05 EP EP12838228.0A patent/EP2763693A4/en not_active Withdrawn
- 2012-10-05 TW TW101136851A patent/TWI565715B/zh not_active IP Right Cessation
- 2012-10-05 EP EP18183149.6A patent/EP3417881A1/en not_active Withdrawn
- 2012-10-05 CA CA2851223A patent/CA2851223A1/en not_active Abandoned
- 2012-10-05 WO PCT/KR2012/008102 patent/WO2013051900A2/en active Application Filing
- 2012-10-08 KR KR1020120111537A patent/KR20130037659A/ko active IP Right Grant
-
2014
- 2014-04-03 IL IL231930A patent/IL231930A0/en unknown
- 2014-04-15 ZA ZA2014/02745A patent/ZA201402745B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3417881A1 (en) | 2018-12-26 |
| TW201331223A (zh) | 2013-08-01 |
| US9597378B2 (en) | 2017-03-21 |
| MX354493B (es) | 2018-03-08 |
| JP6108630B2 (ja) | 2017-04-05 |
| MY168754A (en) | 2018-11-30 |
| EP2763693A2 (en) | 2014-08-13 |
| ZA201402745B (en) | 2016-04-27 |
| AU2012319308B2 (en) | 2017-08-31 |
| WO2013051900A2 (en) | 2013-04-11 |
| RU2014115291A (ru) | 2015-11-20 |
| IL231930A0 (en) | 2014-05-28 |
| AU2012319308A1 (en) | 2014-05-01 |
| SG11201401205UA (en) | 2014-05-29 |
| NZ623726A (en) | 2016-06-24 |
| TWI565715B (zh) | 2017-01-11 |
| RU2620072C2 (ru) | 2017-05-22 |
| MX2014004099A (es) | 2014-05-21 |
| KR20130037659A (ko) | 2013-04-16 |
| CN103974716A (zh) | 2014-08-06 |
| EP2763693A4 (en) | 2015-12-09 |
| US20140271607A1 (en) | 2014-09-18 |
| BR112014008224A2 (pt) | 2017-04-11 |
| CN103974716B (zh) | 2016-08-24 |
| JP2014530018A (ja) | 2014-11-17 |
| WO2013051900A3 (en) | 2013-06-13 |
| CA2851223A1 (en) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088267A1 (es) | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos | |
| BR112014032734A2 (pt) | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| ECSP14012676A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112014031394A8 (pt) | Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| GT201300235A (es) | Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas | |
| MX353964B (es) | Agentes terapeuticos y usos de los mismos. | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| PE20150226A1 (es) | Agentes terapeuticos para administracion subcutanea optimizados | |
| CY1122208T1 (el) | Μεθοδος μετρονομικης χορηγησης προφαρμακων καπτοθεκινης (π.χ. peg-ιρινοτεκανης) | |
| BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga | |
| CO6592015A2 (es) | Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal | |
| BR112015004110A2 (pt) | sistemas e métodos de distribuição de drogas para tratamento de próstata | |
| ECSP10010428A (es) | Derivados de indazol | |
| MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
| CO7170176A2 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo | |
| AU2011347327A8 (en) | uPAR-antagonists and uses thereof | |
| MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| BR112014009761B8 (pt) | Composição de reticulação melhorada entregue por iontoforese, útil para o tratamento de ceratocone | |
| CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
| BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
| MX2018015916A (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |